Posted by Michael Wonder on 29 Nov 2018
Life extending treatment for patients with advanced liver cancer recommended by NICE
29 November 2018 - Approving regorafenib is a "welcome step forward" for those people who are eligible.
A life-extending treatment for some adults with advanced liver cancer has been recommended for use on the NHS by NICE after a rapid review of guidance published earlier in the year.
The drug regorafenib (also called Stivarga and made by Bayer) can now be offered to people with advanced liver cancer if their liver is working well but the diseased area cannot be surgically treated and if they have already taken the life-extending medicine sorafenib.
People must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which means they are fully active and able to carry out normal activities of daily life without restriction, or they are restricted in physically strenuous activity but able to carry out work of a light or sedentary nature.
